People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Pharmaceuticals, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $150.9M | $3.3B | 2018 |
| Redona Therapeutics, Inc. | — | Biotechnology | Series C | $66.8M | $76.2M | 2018 |
| Tallac Therapeutics, Inc. | — | Pharma | Series C | $61.6M | $2.2B | 2020 |
Christine Brennan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christine Brennan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 1 | 13 |
| Luke Evnin | 1 | 12 |
| Todd Foley | 1 | 12 |
| Kush Parmar | 1 | 10 |
| Isaac Cheng | 1 | 9 |
| Briggs Morrison | 1 | 8 |
| Michal Silverberg | 1 | 7 |
| Michael Carusi | 1 | 7 |
| Marian Nakada | 1 | 4 |
| Kazumi Shiosaki | 1 | 4 |
| KUSH M. PARMAR | 1 | 3 |
| Louis Tartaglia | 1 | 3 |
| Carolyn Ng | 1 | 2 |
| John Crowley | 1 | 2 |
| John F. Crowley | 1 | 2 |
| Mario Saltarelli | 1 | 2 |
| Henrijette Richter | 1 | 2 |
| Jaume Pons | 1 | 2 |
| Anja Harmeier | 1 | 2 |
| Dehua Pei | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.